IL7RA haplotype-associated alterations in cellular immune function and gene expression patterns in multiple sclerosis

Genes and Immunity

Volumn 14, Issue 7, 2013, Pages 453-461

  Jager J ^a   Schulze, C ^a   Rosner S ^a   Martin, R ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

interleukin 7 receptor; multiple sclerosis; polymorphism

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR ALPHA; MESSENGER RNA; STAT5 PROTEIN; TRANSCRIPTOME;

ADULT; APOPTOSIS; ARTICLE; BLOOD LEVEL; CD4+ T LYMPHOCYTE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN CELL; IL7RA GENE; IMMUNOSTIMULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; GENE REGULATORY NETWORKS; HAPLOTYPES; HUMANS; INTERLEUKIN-7 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PHOSPHORYLATION; POLYMORPHISM, SINGLE NUCLEOTIDE; STAT5 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC;

EID: 84886720726     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2013.40     Document Type: Article

References (54)

1. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747.
2. Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 2008; 9: 516-526.
3. Olerup O, Hillert J. HLA class II-associated genetic susceptibility in multiple sclerosis: A critical evaluation. Tissue Antigens 1991; 38: 1-15.
4. Kemppinen A, Sawcer S, Compston A. Genome-wide association studies in multiple sclerosis: Lessons and future prospects. Brief Funct Genomics 2011; 10: 61-70.
5. Sawcer S, Hellenthal G, Pirinen M, Spencer CCa, Patsopoulos Na, Moutsianas L et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214-219.
6. Lundmark F, Duvefelt K, Iacobaeus E, Kockum I, Wallström E, Khademi M et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 2007; 39: 1108-1113.
7. Gregory SG, Schmidt S, Seth P, Oksenberg JR, Hart J, Prokop A et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007; 39: 1083-1091.
8. The International Multiple Sclerosis Genetics Consortium. Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851-862.
9. Hoe E, McKay FC, Schibeci SD, Gandhi K, Heard RN, Stewart GJ et al. Functionally significant differences in expression of disease-associated IL-7 receptor alpha haplotypes in CD4 T cells and dendritic cells. J Immunol 2010; 184: 2512-2517.
10. McKay FC, Swain LI, Schibeci SD, Rubio JP, Kilpatrick TJ, Heard RN et al. Haplotypes of the interleukin 7 receptor alpha gene are correlated with altered expression in whole blood cells in multiple sclerosis. Genes Immun 2008; 9: 1-6.
11. Broux B, Hellings N, Venken K, Rummens J-L, Hensen K, Van Wijmeersch B et al. Haplotype 4 of the multiple sclerosis-associated interleukin-7 receptor alpha gene influences the frequency of recent thymic emigrants. Genes Immun 2010; 11: 326-333.
12. Hoe E, McKay F, Schibeci S, Heard R, Stewart G, Booth D. Interleukin 7 receptor alpha chain haplotypes vary in their influence on multiple sclerosis susceptibility and response to interferon Beta. J Interferon Cytokine Res 2010; 30: 291-298.
13. Plum J, De Smedt M, Leclercq G, Verhasselt B, Vandekerckhove B. Interleukin-7 is a critical growth factor in early human T-cell development. Blood 1996; 88: 4239-4245.
14. Zuvich RL, McCauley JL, Oksenberg JR, Sawcer SJ, De Jager PL, Aubin C et al. Genetic variation in the IL7RA/IL7 pathway increases multiple sclerosis susceptibility. Hum Genet 2010; 127: 525-535.
15. Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011; 11: 330-342.
16. Palmer MJ, Mahajan VS, Trajman LC, Irvine DJ, Lauffenburger Da, Chen J. Interleukin-7 receptor signaling network: An integrated systems perspective. Cell Mol Immunol 2008; 5: 79-89.
17. Sorg RV, McLellan AD, Hock BD, Fearnley DB, Hart DN. Human dendritic cells express functional interleukin-7. Immunobiology 1998; 198: 514-526.
18. Mazzucchelli R, Durum SK. Interleukin-7 receptor expression: Intelligent design. Nat Rev Immunol 2007; 7: 144-154.
19. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 2009; 9: 480-490.
20. Van Roon JAG, Glaudemans KAFM, Bijlsma JWJ, Lafeber FPJG. Interleukin 7 stimulates tumour necrosis factor alpha and Th1 cytokine production in joints of patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 113-119.
21. Hartgring SaY, Van Roon JaG, Wenting-van Wijk M, Jacobs KMG, Jahangier ZN, Willis CR et al. Elevated expression of interleukin-7 receptor in inflamed joints mediates interleukin-7-induced immune activation in rheumatoid arthritis. Arthritis Rheum 2009; 60: 2595-2605.
22. Lee L-F, Axtell R, Tu GH, Logronio K, Dilley J, Yu J et al. IL-7 promotes TH1 development and serum IL-7 predicts clinical response to interferon-b in multiple sclerosis. Sci Transl Med 2011; 3: 93ra68-93ra68.
23. Ashbaugh JJ, Brambilla R, Karmally Sa, Cabello C, Malek TR, Bethea Jr. IL7Ra contributes to experimental autoimmune encephalomyelitis through altered T cell responses and nonhematopoietic cell lineages. J Immunol 2013; 190: 4525-4534.
24. Hartgring SAY, Willis CR, Alcorn D, Nelson LJ, Bijlsma JWJ, Lafeber FPJG et al. Blockade of the interleukin-7 receptor inhibits collagen-induced arthritis and is associated with reduction of T cell activity and proinflammatory mediators. Arthritis Rheum 2010; 62: 2716-2725.
25. Pellegrini M, Calzascia T, Toe JG, Preston SP, Lin AE, Elford AR et al. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell 2011; 144: 601-613.
26. Weber F, Fontaine B, Cournu-Rebeix I, Kroner a, Knop M, Lutz S et al. IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes Immun 2008; 9: 259-263.
27. Goodwin RG, Friend D, Ziegler SF, Jerzy R, Falk Ba, Gimpel S et al. Cloning of the human and murine interleukin-7 receptors: Demonstration of a soluble form and homology to a new receptor superfamily. Cell 1990; 60: 941-951.
28. Crawley AM, Faucher S, Angel JB. Soluble IL-7 R alpha (sCD127) inhibits IL-7 activity and is increased in HIV infection. J Immunol 2010; 184: 4679-4687.
29. Blom-Potar M-C, Bugault F, Lambotte O, Delfraissy J-F, Thèze J. Soluble IL-7Ralpha (sCD127) and measurement of IL-7 in the plasma of HIV patients. J Acquir Immune Defic Syndr 2009; 51: 104-105.
30. Rose T, Lambotte O, Pallier C, Delfraissy J-F, Colle J-H. Identification and biochemical characterization of human plasma soluble IL-7R: Lower concentrations in HIV-1-infected patients. J Immunol 2009; 182: 7389-7397.
31. Zhu B, Kang K, Yu J, Chen W. Genome-wide analyses reveal the extent of opportunistic STAT5 binding that does not yield transcriptional activation of neighboring genes. Nucleic Acids Res 2012; 40: 4461-4472.
32. Carrette F, Surh CD. IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasis. Semin Immunol 2012; 24: 209-217.
33. Lee L, Logronio K, Tu GH, Zhai W, Ni I, Mei L et al. Anti-IL-7 receptor-a reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. Proc Natl Acad Sci USA 2012; 109: 12674-12679.
34. Willis CR, Seamons A, Maxwell J, Treuting PM, Nelson L, Chen G et al. Interleukin-7 receptor blockade suppresses adaptive and innate inflammatory responses in experimental colitis. J Inflamm 2012; 9: 39.
35. Kittipatarin C, Khaled AR. Interlinking interleukin-7. Cytokine 2007; 39: 75-83.
36. Perales M-A, Goldberg JD, Yuan J, Koehne G, Lechner L, Papadopoulos EB et al. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood 2012; 120: 4882-4891.
37. Wandinger K, Jabs W, Siekhaus A, Bubel S, Trillenberg P, Wagner H et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 2000; 55: 178-184.
38. Limou S, Melica G, Coulonges C, Lelièvre J-D, Do H, McGinn S et al. Identification of IL7RA risk alleles for rapid progression during HIV-1 infection: A comprehensive study in the GRIV cohort. Curr HIV Res 2012; 10: 143-150.
39. Colonna M, Jonjic S, Watzl C. Natural killer cells: Fighting viruses and much more. Nat Immunol 2011; 12: 107-110.
40. Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 2004; 101: 8705-8708.
41. Munschauer FE, Hartrich LA, Stewart CC, Jacobs L. Circulating natural killer cells but not cytotoxic T lymphocytes are reduced in patients with active relapsing multiple sclerosis and little clinical disability as compared to controls. J Neuroimmunol 1995; 62: 177-181.
42. Bielekova B, Catalfamo M. Regulatory CD56 (bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103: 5941-5946.
43. Gregory AP, Dendrou Ca, Attfield KE, Haghikia A, Xifara DK, Butter F et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 2012; 488: 508-511.
44. Lundström W, Highfill S, Walsh STR, Beq S, Morse E, Kockum I et al. Soluble IL7Ra potentiates IL-7 bioactivity and promotes autoimmunity. Proc Natl Acad Sci USA 2013; 110: E1761-E1770.
45. Kappos L, Antel J, Comi G, Montalban X, O0Connor P, Polman CH et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355: 1124-1140.
46. Hendrickson SL, Lautenberger JA, Chinn LW, Malasky M, Sezgin E, Kingsley LA et al. Genetic variants in nuclear-encoded mitochondrial genes influence AIDS progression. PLoS ONE 2010; 5: 8.
47. Campbell GR, Ohno N, Turnbull DM, Mahad DJ. Mitochondrial changes within axons in multiple sclerosis: An update. Curr Opin Neurol 2012; 25: 221-230.
48. Michaelson MD, Mehler MF, Xu H, Gross RE, Kessler Ja. Interleukin-7 is trophic for embryonic neurons and is expressed in developing brain. Dev Biol 1996; 179: 251-263.
49. Barrette B, Calvo E, Valliè res N, Lacroix S. Transcriptional profiling of the injured sciatic nerve of mice carrying the Wld(S) mutant gene: Identification of genes involved in neuroprotection, neuroinflammation, and nerve regeneration. Brain Behav Immun 2010; 24: 1254-1267.
50. McDonald WI, Compston a, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
51. Barrett J, Fry B, Maller J, Daly M. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
52. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S et al. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
53. Brunet J-P, Tamayo P, Golub TR, Mesirov JP. Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci USA 2004; 101: 4164-4169.
54. Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix factorization. BMC Bioinformatics 2010; 11: 367.